VBI Vaccines Inc. VBIV
Set alert
0.07 USD 0.00 0.00%
At close · Aug 7
0.0574 Day range 0.0866
0.0132 52-week range 1.35
- Open
- 0.0851
- Prev close
- 0.0653
- Mkt cap
- 1.87M
- Vol
- 27.93M
- Avg vol
- 8.54M
- EPS
- -3.54
- P/E
- -0.02
- Div yield
- 0.00%
More statistics
- Low
- 0.0574
- High
- 0.0866
- Forward P/E
- -0.23
- Beta
- 2.17
- Short ratio
- 1.57
- Inst. own
- 13.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.477313
- 200-d avg
- 0.582543
- 1y target
- 5.00
2Y chart
Events in this range
- Apr 12, 2023Split: 1 for 30
- May 15, 2023Earnings: —; estimate -2.27; surprise —%
- Aug 14, 2023Earnings: —; estimate -2.16; surprise —%
- Nov 14, 2023Earnings: —; estimate -0.14; surprise —%
- Apr 1, 2024Earnings: —; estimate -0.22; surprise —%
- May 15, 2024Earnings: —; estimate -0.53; surprise —%
- Aug 12, 2024Earnings: —; estimate 0; surprise —%
Signals (83)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Aug 19, 2024 | 2 years ago |
| RSI: Oversold | Jul 30, 2024 | 2 years ago |
| SMA: Bearish | Jul 23, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jul 19, 2024 | 2 years ago |
| SMA: Bearish | Jul 19, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 18, 2024 | 2 years ago |
| RSI: Overbought | Jul 2, 2024 | 2 years ago |
| SMA: Bullish | Jun 25, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | May 29, 2024 | 2 years ago |
| MACD: Sell Signal | May 29, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| MACD: Buy Signal | May 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bullish | Apr 18, 2024 | 2 years ago |
| SMA: Bearish | Apr 17, 2024 | 2 years ago |
| SMA: Bullish | Apr 16, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 12, 2024 | 2 years ago |
| SMA: Bearish | Apr 11, 2024 | 2 years ago |
| SMA: Bearish | Apr 9, 2024 | 2 years ago |
| SMA: Bullish | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Apr 2, 2024 | 2 years ago |
| SMA: Bullish | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 22, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 19, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Feb 22, 2024 | 2 years ago |
| SMA: Bullish | Feb 21, 2024 | 2 years ago |
| SMA: Bearish | Feb 20, 2024 | 2 years ago |
| SMA: Bullish | Feb 16, 2024 | 2 years ago |
| SMA: Bearish | Feb 14, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 13, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 12, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 8, 2024 | 2 years ago |
| RSI: Overbought | Feb 1, 2024 | 2 years ago |
| SMA: Bullish | Jan 25, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 24, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 23, 2024 | 2 years ago |
| SMA: Bearish | Jan 19, 2024 | 2 years ago |
| SMA: Bullish | Jan 18, 2024 | 2 years ago |
| SMA: Bearish | Jan 12, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 3, 2024 | 2 years ago |
| SMA: Bullish | Jan 2, 2024 | 2 years ago |
| SMA: Bearish | Dec 18, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 15, 2023 | 2 years ago |
| SMA: Bearish | Nov 22, 2023 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 6, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| RSI: Oversold | Sep 18, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 15, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 14, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 20, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 6, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Jun 30, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 26, 2023 | 3 years ago |
| RSI: Oversold | Jun 26, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 20, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 4, 2023 | 3 years ago |
| RSI: Oversold | Apr 4, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 28, 2023 | 3 years ago |
| RSI: Oversold | Mar 23, 2023 | 3 years ago |
| RSI: Oversold | Mar 15, 2023 | 3 years ago |
| RSI: Oversold | Mar 7, 2023 | 3 years ago |
| SMA: Bearish | Feb 21, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 12, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 3, 2023 | 3 years ago |
| RSI: Oversold | Dec 27, 2022 | 3 years ago |
| RSI: Oversold | Dec 22, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 19, 2022 | 3 years ago |
| RSI: Oversold | Dec 19, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 13, 2022 | 3 years ago |
| RSI: Oversold | Dec 2, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 15, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 9, 2022 | 3 years ago |
| RSI: Oversold | Oct 11, 2022 | 4 years ago |
Key statistics
- Market cap
- 1.87M
- Enterprise value
- 38.93M
- Trailing P/E
- 0.00
- Forward P/E
- -0.23
- PEG ratio
- 0.00
- Price / sales
- 0.20
- Price / book
- 0.00
- EPS (TTM)
- -3.54
- Beta
- 2.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 9.41M
- Revenue growth
- 150.30%
- Free cash flow
- -29.10M
- Total cash
- 12.60M
- Total debt
- 50.71M
- Return on equity
- -419.59%
- Shares outstanding
- 28.68M
- Short % of float
- 1.16%
- 50-day average
- 0.477313
- 200-day average
- 0.582543
Analyst view
Consensus: buy
Buy
Price target (mean) 5.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.32.
Financials — quick view
VBIV Revenue — quarterly 1.21M
VBIV Net income — quarterly -17.90M
VBIV EPS — quarterly -0.73
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.53 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | -0.22 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.14 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -2.16 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -2.27 | — | — | — |
About VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vbivaccines.com
News
- VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations
- Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- Dow Jumps Over 300 Points; US Trade Gap Narrows In June
- Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
- Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- VBI Vaccines Announces Results of Annual General Meeting
- VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
- VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
- VBI Vaccines Reports First Quarter 2024 Financial Results
- VBI Vaccines Reports Full Year 2023 Financial Results
Your note
Sign in to keep a note on VBIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON DAVID EVANDER | Officer | Conversion of Exercise of derivative security | Jun 13, 2019 | 148,209 |
| BAXTER JEFFREY ROYSTON | Chief Executive Officer | Purchase | Sep 29, 2019 | 608,255 |
| BEATTIE NELL | Officer | Purchase | Dec 2, 2021 | 68,200 |
| DEWILDE MICHEL | Director | Conversion of Exercise of derivative security | Jun 13, 2019 | 50,000 |
| DIAZ-MITOMA FRANCISCO | Officer | Purchase | Oct 3, 2019 | 0 |
| GILLIS STEVEN | Director | Purchase | Jul 9, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 6.04% | 1,381,355 | 4.54M | Jun 29, 2023 |
| Blackrock Inc. | 0.49% | 112,145 | 368.96K | Jun 29, 2023 |
| Cambridge Investment Research Advisors Inc. | 0.44% | 100,368 | 330.21K | Jun 29, 2023 |
| Millennium Management Llc | 0.39% | 89,205 | 293.48K | Jun 29, 2023 |
| Morgan Stanley | 0.34% | 77,977 | 256.54K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.29% | 67,189 | 221.05K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| General American Investors Co | 0.27% | 62,583 | 205.90K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.26% | 59,707 | 196.44K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.14% | 31,328 | 93.04K | May 30, 2023 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.11% | 26,245 | 77.95K | May 30, 2023 |
| Vanguard Russell 2000 Index Fund | 0.07% | 17,050 | 50.64K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.05% | 11,998 | 35.63K | May 30, 2023 |